US · DRMA
Dermata Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92130
- Website
- dermatarx.com
Price · as of 2024-12-31
$1.33
Market cap 817.87K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $2,232.00 | ||||
| 2022 | $559.20 | ||||
| 2023 | $62.85 | ||||
| 2024 | $12.10 |
AI valuation
Our deep-learning model estimates Dermata Therapeutics, Inc.'s (DRMA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.33
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DRMA | Dermata Therapeutics, Inc… | $1.33 | 817.87K | — | — | — | — | -0.15 | 1.19 | — | 0.11 | — | 1.19 | 0.00% | — | — | -310.44% | 932.57% | -213.46% | 0.00 | — | 1.79 | 1.60 | 0.26 | -7991.00% | — | 7418.00% | -602.98% | -5.66 | 831.94% | 0.00% | 0.00% | 0.04% | 0.10 | 0.12 | — | -36.61 |
| ARTL | Artelo Biosciences, Inc. | $1.19 | 2.75M | — | — | — | — | -0.09 | -0.92 | — | -0.10 | -0.03 | -0.35 | 0.00% | — | — | -1625.11% | 4102.16% | -343.49% | -0.54 | -58.78 | 0.17 | 0.15 | -0.01 | 31049.00% | — | 204.00% | -726.31% | -2.11 | 3064.75% | 0.00% | 0.00% | 0.00% | -0.11 | -0.15 | — | -46.19 |
| ELAB | PMGC Holdings Inc. | $1.19 | 126.21K | +401,467% | +24,631% | — | — | -0.06 | 0.06 | 0.16 | 1.12 | — | 0.10 | 72.84% | -75.65% | -253.14% | -119.12% | -110.26% | -88.07% | 0.00 | -2.54 | 3.36 | 2.22 | 1.25 | -8600.00% | 4407.00% | 2032.00% | -1366.73% | -3.05 | -324.66% | 0.00% | 0.00% | 215.87% | 1.92 | 0.65 | -1.45 | -1.81 |
| GTBP | GT Biopharma, Inc. | $0.48 | 5.08M | — | — | — | — | -0.35 | -2.77 | — | -0.05 | -1.53 | -2.77 | 0.00% | — | — | -453.39% | 238.23% | -143.53% | 0.00 | — | 0.72 | 0.67 | 0.30 | 2305.00% | — | 4577.00% | -278.78% | -2.19 | 214.01% | 0.00% | 0.00% | 63.30% | -0.05 | -0.05 | — | -241.19 |
| PBM | Psyence Biomedical Ltd. | $2.54 | 48.31K | — | — | — | — | 121.05 | 18.22 | — | 113.47 | — | 18.22 | 0.00% | — | — | -47.61% | 1045.66% | 23.95% | 0.00 | -395.15 | 11.04 | 10.55 | -5.98 | -12268.00% | — | 2687.00% | -3.06% | -6.28 | 1068.81% | 0.00% | 0.00% | 12.94% | -31.76 | -31.07 | — | 112.16 |
| REVB | Revelation Biosciences, I… | $1.32 | 1.95M | — | — | — | — | 0.00 | 0.00 | — | 0.67 | — | 0.00 | 0.00% | — | — | -201.08% | 1657.76% | -153.82% | 0.08 | — | 5.41 | 5.36 | 0.67 | -7268.00% | — | 4498931.00% | -103262.37% | -4.14 | 1511.33% | 74316.81% | -66.80% | 198525.74% | 1.10 | 1.20 | — | -7.64 |
| VRAX | Virax Biolabs Group Limit… | $0.23 | 988.66K | +58,899% | +71% | — | +71,836% | -0.50 | 0.53 | 478.92 | 0.14 | — | 0.54 | -838.21% | -97344.76% | -95739.17% | -109.69% | -313.42% | -101.88% | 0.07 | -105.93 | 7.27 | 6.33 | 0.66 | -4196.00% | -9595.00% | -3028.00% | -170.43% | -6.78 | -268.72% | 0.00% | 0.00% | 16.06% | 0.13 | 0.16 | -129.50 | -5.85 |
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
- CEO
- Gerald T. Proehl
- Employees
- 8
- Beta
- 0.55
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.33) − 1 = — (DCF, example).